Combining inhibitors of the histone demethylase KDM4B, such as methylstat and PI3K/AKT inhibitors, upregulates the UPR downstream target ATF4, resulting in UPR activation and the apoptosis of PTEN-deficient breast cancer cells [196]. Here, PIK3CA is linked to breast cancer.